CN103260624B - 拉喹莫德用于在多发性硬化症患者中减少疲劳、改善功能状态和改善生活品质的用途 - Google Patents

拉喹莫德用于在多发性硬化症患者中减少疲劳、改善功能状态和改善生活品质的用途 Download PDF

Info

Publication number
CN103260624B
CN103260624B CN201180060414.8A CN201180060414A CN103260624B CN 103260624 B CN103260624 B CN 103260624B CN 201180060414 A CN201180060414 A CN 201180060414A CN 103260624 B CN103260624 B CN 103260624B
Authority
CN
China
Prior art keywords
laquinimod
multiple sclerosis
patient
months
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180060414.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN103260624A (zh
Inventor
诺拉·塔克斯克
丹·巴-佐哈尔
迪娜·科夫勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46162796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103260624(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of CN103260624A publication Critical patent/CN103260624A/zh
Application granted granted Critical
Publication of CN103260624B publication Critical patent/CN103260624B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201180060414.8A 2010-12-07 2011-12-06 拉喹莫德用于在多发性硬化症患者中减少疲劳、改善功能状态和改善生活品质的用途 Expired - Fee Related CN103260624B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US42074210P 2010-12-07 2010-12-07
US61/420,742 2010-12-07
US201161542996P 2011-10-04 2011-10-04
US61/542,996 2011-10-04
PCT/US2011/063460 WO2012078591A1 (en) 2010-12-07 2011-12-06 Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients

Publications (2)

Publication Number Publication Date
CN103260624A CN103260624A (zh) 2013-08-21
CN103260624B true CN103260624B (zh) 2015-06-03

Family

ID=46162796

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180060414.8A Expired - Fee Related CN103260624B (zh) 2010-12-07 2011-12-06 拉喹莫德用于在多发性硬化症患者中减少疲劳、改善功能状态和改善生活品质的用途

Country Status (19)

Country Link
US (1) US20120142730A1 (cg-RX-API-DMAC7.html)
EP (1) EP2648732A4 (cg-RX-API-DMAC7.html)
JP (2) JP2013544887A (cg-RX-API-DMAC7.html)
KR (1) KR20130124518A (cg-RX-API-DMAC7.html)
CN (1) CN103260624B (cg-RX-API-DMAC7.html)
AU (2) AU2011338647A1 (cg-RX-API-DMAC7.html)
BR (1) BR112013014061A2 (cg-RX-API-DMAC7.html)
CA (1) CA2820586A1 (cg-RX-API-DMAC7.html)
CL (1) CL2013001602A1 (cg-RX-API-DMAC7.html)
EA (1) EA201390827A1 (cg-RX-API-DMAC7.html)
IL (1) IL250726A0 (cg-RX-API-DMAC7.html)
MX (1) MX2013006464A (cg-RX-API-DMAC7.html)
NZ (1) NZ611628A (cg-RX-API-DMAC7.html)
PE (1) PE20140872A1 (cg-RX-API-DMAC7.html)
PH (1) PH12013501193A1 (cg-RX-API-DMAC7.html)
SG (2) SG10201509831XA (cg-RX-API-DMAC7.html)
UA (1) UA111959C2 (cg-RX-API-DMAC7.html)
WO (1) WO2012078591A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201304237B (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0617477A2 (pt) * 2005-10-19 2011-07-26 Teva Pharma mistura de partÍculas cristalinas de laquinimod sàdica, composiÇço, processo de cristalizaÇço de laquinimod sàdica, laquinimod sàdica, e, processo para produzir uma composiÇço farmacÊutica
WO2009082471A1 (en) 2007-12-20 2009-07-02 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
BR112012002124A2 (pt) * 2009-07-30 2015-09-15 Teva Pharma tratamento da doença de crohn com laquinimode.
WO2011019375A1 (en) 2009-08-10 2011-02-17 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
EA201290860A1 (ru) * 2010-03-03 2013-04-30 Тева Фармасьютикал Индастриз Лтд. Лечение ревматоидного артрита комбинацией лаквинимода и метотрексата
KR20130006640A (ko) * 2010-03-03 2013-01-17 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드를 이용한 루푸스 신장염의 치료
AU2011274496B2 (en) 2010-07-09 2016-03-10 Teva Pharmaceutical Industries Ltd. Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
SG11201401330YA (en) 2011-10-12 2014-05-29 Teva Pharma Treatment of multiple sclerosis with combination of laquinimod and fingolimod
WO2013116657A1 (en) 2012-02-03 2013-08-08 Teva Pharmaceutical Industries Ltd. USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY
MX2014009889A (es) 2012-02-16 2014-11-13 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos.
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma N-乙基-4-羥基-1-甲基-5-(甲基(2,3,4,5,6-五羥基己基)胺基)-2-側氧-n-苯基-1,2-二氫喹啉-3-甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療gaba媒介之疾病之拉喹莫德(laquinimod)
US20150209346A1 (en) * 2012-09-27 2015-07-30 Teva Pharmaceutical Industries, Ltd. Combination of laquinimod and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
MX2015004564A (es) * 2012-10-12 2015-07-21 Teva Pharma Laquinimod para producir el daño talamico en la esclerosis multiple.
EA201590788A1 (ru) 2012-11-07 2015-12-30 Тева Фармасьютикал Индастриз Лтд. Аминные соли лахинимода
KR20150119227A (ko) * 2013-02-15 2015-10-23 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드에 의한 다발성 경화증의 진행형 형태의 치료
JP2016514162A (ja) 2013-03-14 2016-05-19 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドナトリウムの結晶およびその製造のための改善された方法
WO2014152009A1 (en) 2013-03-14 2014-09-25 Teva Pharmaceutical Industries Ltd. Transdermal formulations of laquinimod
BR112016014507A2 (pt) * 2013-12-20 2018-05-22 Teva Pharma uso de laquinimod para retardar progressão da doença de huntington
EP3094330A4 (en) * 2014-01-17 2017-09-27 Teva Pharmaceutical Industries Ltd Treatment of crohn's disease using low doses of laquinimod
HK1231413A1 (zh) 2014-04-29 2017-12-22 Teva Pharmaceutical Industries Ltd. 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德
CA2964315A1 (en) 2014-10-16 2016-04-21 Novartis Ag Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis
WO2016106142A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
EP3863628B1 (en) * 2018-10-09 2023-12-27 MediciNova, Inc. Combination of ibudilast and interferon-beta and methods of using same
MX2022000835A (es) * 2019-07-22 2022-02-10 Actelion Pharmaceuticals Ltd Metodos para tratar la esclerosis multiple.
CN110688373A (zh) * 2019-09-17 2020-01-14 杭州绿度信息技术有限公司 一种基于逻辑回归的offset方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007146248A2 (en) * 2006-06-12 2007-12-21 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
US20090081259A1 (en) * 2004-12-22 2009-03-26 Merz Pharma Gmbh & Co. Kgaa 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
US20090148462A1 (en) * 2005-10-13 2009-06-11 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20160455T1 (hr) * 2004-09-09 2016-07-15 Yeda Research And Development Co., Ltd. Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
EP2653873B8 (en) * 2007-02-08 2022-08-24 Biogen MA Inc. Compositions and uses for treating Multiple Sclerosis
NZ597378A (en) * 2009-06-19 2014-08-29 Teva Pharma Treatment of multiple sclerosis with laquinimod

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090081259A1 (en) * 2004-12-22 2009-03-26 Merz Pharma Gmbh & Co. Kgaa 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
US20090148462A1 (en) * 2005-10-13 2009-06-11 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
WO2007146248A2 (en) * 2006-06-12 2007-12-21 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations

Also Published As

Publication number Publication date
BR112013014061A2 (pt) 2016-09-13
JP2013544887A (ja) 2013-12-19
EP2648732A1 (en) 2013-10-16
CL2013001602A1 (es) 2013-10-25
MX2013006464A (es) 2013-07-29
EA201390827A1 (ru) 2013-12-30
IL250726A0 (en) 2017-04-30
WO2012078591A8 (en) 2012-08-02
NZ611628A (en) 2015-06-26
UA111959C2 (uk) 2016-07-11
SG190449A1 (en) 2013-07-31
AU2011338647A1 (en) 2013-07-04
JP2017095476A (ja) 2017-06-01
AU2011338647A8 (en) 2013-09-05
PE20140872A1 (es) 2014-08-09
US20120142730A1 (en) 2012-06-07
WO2012078591A1 (en) 2012-06-14
CA2820586A1 (en) 2012-06-14
PH12013501193A1 (en) 2013-07-15
ZA201304237B (en) 2014-08-27
KR20130124518A (ko) 2013-11-14
AU2017202055A1 (en) 2017-04-20
CN103260624A (zh) 2013-08-21
SG10201509831XA (en) 2015-12-30
EP2648732A4 (en) 2014-04-30

Similar Documents

Publication Publication Date Title
DK2442651T3 (en) Treatment of multiple sclerosis with laquinimod
US20120142730A1 (en) Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
US20160296511A1 (en) Laquinimod for reducing thalamic damage in multiple sclerosis
US9662322B2 (en) Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status
HK1169563B (en) Treatment of multiple sclerosis with laquinimod

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150603

Termination date: 20181206

CF01 Termination of patent right due to non-payment of annual fee